Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance

Abstract Background Spreading Plasmodium falciparum artemisinin drug resistance threatens global malaria public health gains. Limited data exist to define the extent of P. falciparum artemisinin resistance southeast of the Greater Mekong region in Malaysia. Methods A clinical efficacy study of oral...

Full description

Bibliographic Details
Published in:Malaria Journal
Main Authors: Matthew J. Grigg, Timothy William, Kim A. Piera, Giri S. Rajahram, Jenarun Jelip, Ammar Aziz, Jayaram Menon, Jutta Marfurt, Ric N. Price, Sarah Auburn, Bridget E. Barber, Tsin W. Yeo, Nicholas M. Anstey
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2018
Subjects:
Online Access:https://doi.org/10.1186/s12936-018-2593-x
https://doaj.org/article/1c30bf558fcf4dba809bed709ab62968
_version_ 1821839057764745216
author Matthew J. Grigg
Timothy William
Kim A. Piera
Giri S. Rajahram
Jenarun Jelip
Ammar Aziz
Jayaram Menon
Jutta Marfurt
Ric N. Price
Sarah Auburn
Bridget E. Barber
Tsin W. Yeo
Nicholas M. Anstey
author_facet Matthew J. Grigg
Timothy William
Kim A. Piera
Giri S. Rajahram
Jenarun Jelip
Ammar Aziz
Jayaram Menon
Jutta Marfurt
Ric N. Price
Sarah Auburn
Bridget E. Barber
Tsin W. Yeo
Nicholas M. Anstey
author_sort Matthew J. Grigg
collection Directory of Open Access Journals: DOAJ Articles
container_issue 1
container_title Malaria Journal
container_volume 17
description Abstract Background Spreading Plasmodium falciparum artemisinin drug resistance threatens global malaria public health gains. Limited data exist to define the extent of P. falciparum artemisinin resistance southeast of the Greater Mekong region in Malaysia. Methods A clinical efficacy study of oral artesunate (total target dose 12 mg/kg) daily for 3 days was conducted in patients with uncomplicated falciparum malaria and a parasite count < 100,000/µL admitted to 3 adjacent district hospitals in Sabah, East Malaysia. On day 3 and 4 all patients were administered split dose mefloquine (total dose 25 mg/kg) and followed for 28 days. Twenty-one kelch13 polymorphisms associated with P. falciparum artemisinin resistance were also evaluated in P. falciparum isolates collected from patients presenting to health facilities predominantly within the tertiary referral area of western Sabah between 2012 and 2016. Results In total, 49 patients were enrolled and treated with oral artesunate. 90% (44/49) of patients had cleared their parasitaemia by 48 h and 100% (49/49) within 72 h. The geometric mean parasite count at presentation was 9463/µL (95% CI 6757–13,254), with a median time to 50% parasite clearance of 4.3 h (IQR 2.0–8.4). There were 3/45 (7%) patients with a parasite clearance slope half-life of ≥ 5 h. All 278 P. falciparum isolates evaluated were wild-type for kelch13 markers. Conclusion There is no suspected or confirmed evidence of endemic artemisinin-resistant P. falciparum in this pre-elimination setting in Sabah, Malaysia. Current guidelines recommending first-line treatment with ACT remain appropriate for uncomplicated malaria in Sabah, Malaysia. Ongoing surveillance is needed southeast of the Greater Mekong sub-region.
format Article in Journal/Newspaper
genre Arctic
genre_facet Arctic
geographic Arctic
geographic_facet Arctic
id ftdoajarticles:oai:doaj.org/article:1c30bf558fcf4dba809bed709ab62968
institution Open Polar
language English
op_collection_id ftdoajarticles
op_doi https://doi.org/10.1186/s12936-018-2593-x
op_relation http://link.springer.com/article/10.1186/s12936-018-2593-x
https://doaj.org/toc/1475-2875
doi:10.1186/s12936-018-2593-x
1475-2875
https://doaj.org/article/1c30bf558fcf4dba809bed709ab62968
op_source Malaria Journal, Vol 17, Iss 1, Pp 1-8 (2018)
publishDate 2018
publisher BMC
record_format openpolar
spelling ftdoajarticles:oai:doaj.org/article:1c30bf558fcf4dba809bed709ab62968 2025-01-16T20:44:10+00:00 Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance Matthew J. Grigg Timothy William Kim A. Piera Giri S. Rajahram Jenarun Jelip Ammar Aziz Jayaram Menon Jutta Marfurt Ric N. Price Sarah Auburn Bridget E. Barber Tsin W. Yeo Nicholas M. Anstey 2018-12-01T00:00:00Z https://doi.org/10.1186/s12936-018-2593-x https://doaj.org/article/1c30bf558fcf4dba809bed709ab62968 EN eng BMC http://link.springer.com/article/10.1186/s12936-018-2593-x https://doaj.org/toc/1475-2875 doi:10.1186/s12936-018-2593-x 1475-2875 https://doaj.org/article/1c30bf558fcf4dba809bed709ab62968 Malaria Journal, Vol 17, Iss 1, Pp 1-8 (2018) Plasmodium falciparum Malaria kelch K13 Artemisinin-resistance Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 article 2018 ftdoajarticles https://doi.org/10.1186/s12936-018-2593-x 2022-12-31T15:19:18Z Abstract Background Spreading Plasmodium falciparum artemisinin drug resistance threatens global malaria public health gains. Limited data exist to define the extent of P. falciparum artemisinin resistance southeast of the Greater Mekong region in Malaysia. Methods A clinical efficacy study of oral artesunate (total target dose 12 mg/kg) daily for 3 days was conducted in patients with uncomplicated falciparum malaria and a parasite count < 100,000/µL admitted to 3 adjacent district hospitals in Sabah, East Malaysia. On day 3 and 4 all patients were administered split dose mefloquine (total dose 25 mg/kg) and followed for 28 days. Twenty-one kelch13 polymorphisms associated with P. falciparum artemisinin resistance were also evaluated in P. falciparum isolates collected from patients presenting to health facilities predominantly within the tertiary referral area of western Sabah between 2012 and 2016. Results In total, 49 patients were enrolled and treated with oral artesunate. 90% (44/49) of patients had cleared their parasitaemia by 48 h and 100% (49/49) within 72 h. The geometric mean parasite count at presentation was 9463/µL (95% CI 6757–13,254), with a median time to 50% parasite clearance of 4.3 h (IQR 2.0–8.4). There were 3/45 (7%) patients with a parasite clearance slope half-life of ≥ 5 h. All 278 P. falciparum isolates evaluated were wild-type for kelch13 markers. Conclusion There is no suspected or confirmed evidence of endemic artemisinin-resistant P. falciparum in this pre-elimination setting in Sabah, Malaysia. Current guidelines recommending first-line treatment with ACT remain appropriate for uncomplicated malaria in Sabah, Malaysia. Ongoing surveillance is needed southeast of the Greater Mekong sub-region. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Malaria Journal 17 1
spellingShingle Plasmodium falciparum
Malaria
kelch
K13
Artemisinin-resistance
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Matthew J. Grigg
Timothy William
Kim A. Piera
Giri S. Rajahram
Jenarun Jelip
Ammar Aziz
Jayaram Menon
Jutta Marfurt
Ric N. Price
Sarah Auburn
Bridget E. Barber
Tsin W. Yeo
Nicholas M. Anstey
Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance
title Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance
title_full Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance
title_fullStr Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance
title_full_unstemmed Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance
title_short Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance
title_sort plasmodium falciparum artemisinin resistance monitoring in sabah, malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance
topic Plasmodium falciparum
Malaria
kelch
K13
Artemisinin-resistance
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
topic_facet Plasmodium falciparum
Malaria
kelch
K13
Artemisinin-resistance
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
url https://doi.org/10.1186/s12936-018-2593-x
https://doaj.org/article/1c30bf558fcf4dba809bed709ab62968